Abstract

Purpose: Patients who have experienced failure of arthroscopic labral reconstruction of the hip have traditionally been left with limited options, such as living with pain and dysfunction, or undergoing hip arthroplasty. The purpose of our study was to evaluate the outcomes of revision arthroscopic circumferential allograft labral reconstruction (CLR) in nonarthritic hips which had previously undergone labral reconstruction by the same surgeon.

Method: Data from 24 hips (∼ 1% of the lead author’s surgical panel during a 4-year collection period) were evaluated to determine the efficacy of revision CLR based on validated patient-reported outcomes.

Results: The success rate of the operation was 96%. PROs demonstrated statistically significant improvement with strong measures of effect. Modified Hip Harris Scores (mHHS) improved by a mean of 26.68 points. 88% of patients met the minimal clinically important difference (MCID) for mHHS (+6.49, p < .001, d = 1.32), and the majority of these patients met the patient acceptable symptom state (PASS) threshold. Lower Extremity Functional Scale (LEFS) scores improved by a mean of 21.88 points. 78% of patients met the MCID (+7.79, p < .001, d = 1.32) for LEFS.

Conclusion: While labral reconstruction has broadly been shown to result in highly favorable outcomes, our study demonstrated that in the rare case of failure, revision CLR is not only feasible, but results in improved pain and functionality.

This content is only available as a PDF.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact [email protected].